What type of study is this?

This is a Human Clinical Trial study (also classified as: Phase 3).

November 25, 2025Open Access

Efficacy and safety of Ivarmacitinib in moderate-to-severe atopic dermatitis patients with or without previous systemic treatments: a post-hoc analysis of a phase III trial

Key Points

Key points are not available for this paper at this time.

Abstract

Ivarmacitinib demonstrates good efficacy and a favorable safety profile in moderate-to-severe AD patients, irrespective of previous systemic treatments.

Efficacy and safety of Ivarmacitinib in moderate-to-severe atopic dermatitis patients with or without previous systemic treatments: a post-hoc analysis of a phase III trial

Key Points

Abstract

Cite This Study